A Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials 1 Year after Starting Sodium-glucose Transporter-2 Inhibitors in Heart Failure Patients with Reduced Ventricular Ejection Fraction

Introduction: The Sodium-Glucose Cotransporter-2 Inhibitor (SGLT-2 inhibitor) is a diabetic medication. Recently, there has been enough evidence of SGLT-2 inhibitors in type 2 diabetes mellitus, driving an abatement cardiovascular breakdown hospitalization. To explore inhibitor with lower discharge portion, we led orderly survey and meta-examination. Strategies: We played out methodical writing search from various electronic databases. used keywords:” '' “Heart Failure.” Inclusion criteria are randomized placebo-controlled trial, one-year follow-up ejection fraction 40% or less. Composite endpoint mortality hospitalization heart failure. Individual outcomes include all-cause mortality, passing, For low heterogeneity scores, results introduced utilizing danger proportion (RR) 95 percent certainty stretch statistical analysis using fixed-effect model.
 Results: Total two control trial was selected (DAPA-HF [Dapagliflozin] EMPEROR-Reduced [Empagliflozin]) 8,474 patients pooled within our analysis. the composite outcome compared placebo had significant decrease passing (RR=0.78 [95% CI, 0.71–0.84], p<0.00001; I2=0%). Result individual showed reduction (RR=0.88 0.79 – 0.98], p=0.03; I2=1%), (RR=0.87 0.77 0.99], I2=0%) failure (RR=0.72 0.65–0.81], Conclusion: Within one year treatment inhibitor, hospitalization, significantly reduced.